These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33907692)

  • 1. TNFR2: Role in Cancer Immunology and Immunotherapy.
    Yang Y; Islam MS; Hu Y; Chen X
    Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis.
    Ye LL; Peng WB; Niu YR; Xiang X; Wei XS; Wang ZH; Wang X; Zhang SY; Chen X; Zhou Q
    Ann Transl Med; 2020 Dec; 8(24):1647. PubMed ID: 33490159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
    Liao P; Jiang M; Islam MS; Wang Y; Chen X
    Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Zou H; Li R; Hu H; Hu Y; Chen X
    Front Immunol; 2018; 9():594. PubMed ID: 29632537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4
    Islam MS; Yang Y; Chen X
    Adv Exp Med Biol; 2021; 1278():257-272. PubMed ID: 33523452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
    Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
    Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
    Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
    He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
    Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells.
    Kampan NC; Madondo MT; McNally OM; Stephens AN; Quinn MA; Plebanski M
    Front Immunol; 2017; 8():1482. PubMed ID: 29163543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
    Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
    Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and
    Shaikh F; He J; Bhadra P; Chen X; Siu SWI
    Front Immunol; 2018; 9():1382. PubMed ID: 29967617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.
    Li M; Zhang X; Bai X; Liang T
    Front Oncol; 2022; 12():862154. PubMed ID: 35494080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.